Answers are grounded in this paper and cite their sources.
Objective: To explore the effect of N-acetylcysteine combined with lung rehabilitation therapy on exercise endurance and quality of life in patients with rheumatoid arthritis-related interstitial lung disease (RA-ILD). Methods: Fifty-six patients with RA-ILD admitted to Xijing Hospital from May 2022 to January 2024 were randomly divided into two groups: a non-rehabilitation group and a pulmonary rehabilitation group, with 28 patients in each group. Both groups received routine treatment. Additionally, the non-rehabilitation group received N-acetylcysteine treatment, while the lung rehabilitation group received lung rehabilitation treatment in addition to N-acetylcysteine. The improvement in exercise endurance and dyspnea between the two groups after treatment was compared and the quality of life of the patients was observed. Results: After treatment, the exercise endurance score in the lung rehabilitation group (335.67 ± 45.29) was higher than that in the non-rehabilitation group (P < 0.05). The dyspnea score in the lung rehabilitation group (0.72 ± 0.16) was lower than that in the non-rehabilitation group (P < 0.05). Additionally, FVC (3.18 ± 0.58 L), FEV1 (2.28 ± 0.56 L), FEV1/FVC (69.69 ± 5.56), and DLCO (60.53 ± 5.92 mL/mmHg/min) were higher in the lung rehabilitation group compared to the non-rehabilitation group after treatment (P < 0.05). Conclusion: Lung rehabilitation therapy combined with N-acetylcysteine treatment can effectively improve dyspnea symptoms, lung function, and exercise endurance in patients with RA-ILD. This approach helps to improve patient’s quality of life and is beneficial for their prognosis.
No takes yet. Share an insight, caveat, or question.
Ying Li (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: